[Form 4] Unicycive Therapeutics, Inc. Insider Trading Activity
Unicycive Therapeutics director Gaurav Aggarwal reported a Form 4 disclosing a non-derivative purchase of 652,900 shares of common stock on 08/25/2025. Following the transaction, the report shows beneficial ownership of 1,789,915 shares attributed indirectly through Vivo Opportunity Fund Holdings L.P., of which the reporting person is a managing member. The filing also reports a disposition of 3,199.21 shares of Series A-2 Prime Preferred Stock (issued March 14, 2024) and explains each preferred share converts using an original per-share price of $1,000 divided by $4.90, subject to blocking provisions. The reporting person disclaims beneficial ownership except for pecuniary interest.
Gaurav Aggarwal, amministratore di Unicycive Therapeutics, ha presentato un Form 4 che dichiara un acquisto non derivato di 652.900 azioni ordinarie in data 25/08/2025. Dopo l'operazione, il documento indica una partecipazione beneficiaria di 1.789.915 azioni attribuita indirettamente tramite Vivo Opportunity Fund Holdings L.P., di cui il dichiarante 猫 membro gestore. La comunicazione riporta inoltre la cessione di 3.199,21 azioni di Series A-2 Prime Preferred Stock (emesse il 14 marzo 2024) e spiega che ogni azione privilegiata si converte calcolando il prezzo originario per azione di $1.000 diviso $4,90, soggetto a vincoli di blocco. Il dichiarante rinuncia alla qualifica di proprietario beneficiario, fatta eccezione per l'interesse pecuniario.
Gaurav Aggarwal, director de Unicycive Therapeutics, present贸 un Form 4 que revela una compra no derivada de 652.900 acciones ordinarias el 25/08/2025. Tras la operaci贸n, el informe muestra una titularidad beneficiaria de 1.789.915 acciones atribuida de forma indirecta a trav茅s de Vivo Opportunity Fund Holdings L.P., de la que el declarante es miembro gestor. La presentaci贸n tambi茅n informa de la enajenaci贸n de 3.199,21 acciones de Series A-2 Prime Preferred Stock (emitidas el 14 de marzo de 2024) y aclara que cada acci贸n preferente se convierte usando un precio original por acci贸n de $1.000 dividido por $4,90, sujeto a cl谩usulas de bloqueo. El declarante renuncia a la condici贸n de titular beneficiario salvo por un inter茅s pecuniario.
Unicycive Therapeutics 鞚挫偓 Gaurav Aggarwal電� 2025-08-25鞛愲 牍勴寣靸� 毵れ垬 雮挫棴鞚� 瓿店皽頃橂姅 Form 4毳� 鞝滌稖頄堨溂氅�, 652,900欤� 氤错喌欤�毳� 毵れ垬頃� 瓴冹溂搿� 氤搓碃霅橃棃鞀惦媹雼�. 瓯半灅 頉� 氤搓碃靹滌棎電� 氤搓碃鞚胳澊 甏�毽� 氅る矂搿� 鞛堧姅 Vivo Opportunity Fund Holdings L.P.毳� 韱淀暣 臧勳爲鞝侅溂搿� 攴�靻嶋悳 1,789,915欤�鞚� 鞁れ 靻岇湢臧� 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊電� 霕愴暅 3,199.21欤� Series A-2 Prime 鞖办劆欤�(2024-03-14 氚滍枆)鞚� 觳橂秳鞚� 氤搓碃頃橁碃, 臧� 鞖办劆欤茧姅 鞗愳＜雼� 臧�瓴� $1,000鞚� $4.90搿� 雮橂垐 臧掛溂搿� 鞝勴櫂霅橂┌ 霛届梾 臁绊暛鞚� 鞝侅毄鞚� 氚涬姅雼り碃 靹る獏頃╇媹雼�. 氤搓碃鞚胳潃 旮堨爠鞝� 鞚挫澋鞚� 鞝滌櫢頃� 鞁れ鞝� 靻岇湢甓岇潉 攵�鞚疙暕雼堧嫟.
Gaurav Aggarwal, administrateur de Unicycive Therapeutics, a d茅pos茅 un Form 4 r茅v茅lant un achat non d茅riv茅 de 652鈥�900 actions ordinaires le 25/08/2025. Apr猫s la transaction, le rapport indique une d茅tention b茅n茅ficiaire de 1鈥�789鈥�915 actions attribu茅e indirectement via Vivo Opportunity Fund Holdings L.P., dont la personne d茅clarant est membre gestionnaire. Le d茅p么t signale 茅galement une cession de 3鈥�199,21 actions de Series A-2 Prime Preferred Stock (茅mises le 14 mars 2024) et pr茅cise que chaque action privil茅gi茅e se convertit en utilisant un prix initial par action de 1鈥�000 $ divis茅 par 4,90 $, sous r茅serve de clauses de blocage. La personne d茅clarant d茅cline la qualit茅 de propri茅taire b茅n茅ficiaire, 脿 l'exception d'un int茅r锚t p茅cuniaire.
Gaurav Aggarwal, Direktor von Unicycive Therapeutics, meldete in einem Form 4 einen nicht-derivativen Kauf von 652.900 Stammaktien am 25.08.2025. Nach der Transaktion weist die Meldung einen wirtschaftlich berechtigten Anteil von 1.789.915 Aktien aus, der indirekt 眉ber Vivo Opportunity Fund Holdings L.P. zugerechnet wird, bei dem die meldende Person gesch盲ftsf眉hrendes Mitglied ist. Die Einreichung berichtet au脽erdem 眉ber die Ver盲u脽erung von 3.199,21 Aktien der Series A-2 Prime Preferred Stock (ausgegeben am 14. M盲rz 2024) und erkl盲rt, dass jede Vorzugsaktie unter Verwendung des urspr眉nglichen St眉ckpreises von $1.000 geteilt durch $4,90 umgewandelt wird, vorbehaltlich Sperrklauseln. Die meldende Person weist die wirtschaftliche Berechtigung mit Ausnahme eines pecuni盲ren Interesses zur眉ck.
- None.
- None.
Insights
TL;DR: Director increased reported common stock holdings indirectly via affiliated fund; preferred-to-common conversion terms reiterated.
The Form 4 shows a material acquisition of 652,900 common shares on 08/25/2025 recorded as an indirect holding through Vivo Opportunity Fund Holdings L.P. The filing clarifies the reporting person is a managing member of the GP and disclaims direct beneficial ownership except for pecuniary interest, which is standard for fund-related holdings. The disclosure of Series A-2 Prime Preferred Stock conversion mechanics is notable because it restates the conversion ratio derived from a $1,000 original per-share price and a $4.90 divisor, which affects potential common share dilution if conversions occur. No prices for the common share purchase are reported in the non-derivative section; however, the transaction code indicates an acquisition. Overall, the filing is a routine insider disclosure of fund-managed holdings with convertible preferred context.
TL;DR: Disclosure aligns with Section 16 norms; the reporting person properly attributes holdings to an affiliated fund and includes conversion detail for preferred stock.
The Form 4 appropriately identifies the reporting person as a director and the indirect ownership via Vivo Opportunity Fund Holdings L.P., with a standard disclaimer of beneficial ownership beyond pecuniary interest. The reporting of 1,789,915 beneficial shares after the transaction provides transparency on aggregate exposure. The note that Series A-2 Prime Preferred Stock was issued March 14, 2024 and lacks an expiration date is material to governance and capital structure transparency. No amendments or pricing inconsistencies are evident within the filing text provided.
Gaurav Aggarwal, amministratore di Unicycive Therapeutics, ha presentato un Form 4 che dichiara un acquisto non derivato di 652.900 azioni ordinarie in data 25/08/2025. Dopo l'operazione, il documento indica una partecipazione beneficiaria di 1.789.915 azioni attribuita indirettamente tramite Vivo Opportunity Fund Holdings L.P., di cui il dichiarante 猫 membro gestore. La comunicazione riporta inoltre la cessione di 3.199,21 azioni di Series A-2 Prime Preferred Stock (emesse il 14 marzo 2024) e spiega che ogni azione privilegiata si converte calcolando il prezzo originario per azione di $1.000 diviso $4,90, soggetto a vincoli di blocco. Il dichiarante rinuncia alla qualifica di proprietario beneficiario, fatta eccezione per l'interesse pecuniario.
Gaurav Aggarwal, director de Unicycive Therapeutics, present贸 un Form 4 que revela una compra no derivada de 652.900 acciones ordinarias el 25/08/2025. Tras la operaci贸n, el informe muestra una titularidad beneficiaria de 1.789.915 acciones atribuida de forma indirecta a trav茅s de Vivo Opportunity Fund Holdings L.P., de la que el declarante es miembro gestor. La presentaci贸n tambi茅n informa de la enajenaci贸n de 3.199,21 acciones de Series A-2 Prime Preferred Stock (emitidas el 14 de marzo de 2024) y aclara que cada acci贸n preferente se convierte usando un precio original por acci贸n de $1.000 dividido por $4,90, sujeto a cl谩usulas de bloqueo. El declarante renuncia a la condici贸n de titular beneficiario salvo por un inter茅s pecuniario.
Unicycive Therapeutics 鞚挫偓 Gaurav Aggarwal電� 2025-08-25鞛愲 牍勴寣靸� 毵れ垬 雮挫棴鞚� 瓿店皽頃橂姅 Form 4毳� 鞝滌稖頄堨溂氅�, 652,900欤� 氤错喌欤�毳� 毵れ垬頃� 瓴冹溂搿� 氤搓碃霅橃棃鞀惦媹雼�. 瓯半灅 頉� 氤搓碃靹滌棎電� 氤搓碃鞚胳澊 甏�毽� 氅る矂搿� 鞛堧姅 Vivo Opportunity Fund Holdings L.P.毳� 韱淀暣 臧勳爲鞝侅溂搿� 攴�靻嶋悳 1,789,915欤�鞚� 鞁れ 靻岇湢臧� 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊電� 霕愴暅 3,199.21欤� Series A-2 Prime 鞖办劆欤�(2024-03-14 氚滍枆)鞚� 觳橂秳鞚� 氤搓碃頃橁碃, 臧� 鞖办劆欤茧姅 鞗愳＜雼� 臧�瓴� $1,000鞚� $4.90搿� 雮橂垐 臧掛溂搿� 鞝勴櫂霅橂┌ 霛届梾 臁绊暛鞚� 鞝侅毄鞚� 氚涬姅雼り碃 靹る獏頃╇媹雼�. 氤搓碃鞚胳潃 旮堨爠鞝� 鞚挫澋鞚� 鞝滌櫢頃� 鞁れ鞝� 靻岇湢甓岇潉 攵�鞚疙暕雼堧嫟.
Gaurav Aggarwal, administrateur de Unicycive Therapeutics, a d茅pos茅 un Form 4 r茅v茅lant un achat non d茅riv茅 de 652鈥�900 actions ordinaires le 25/08/2025. Apr猫s la transaction, le rapport indique une d茅tention b茅n茅ficiaire de 1鈥�789鈥�915 actions attribu茅e indirectement via Vivo Opportunity Fund Holdings L.P., dont la personne d茅clarant est membre gestionnaire. Le d茅p么t signale 茅galement une cession de 3鈥�199,21 actions de Series A-2 Prime Preferred Stock (茅mises le 14 mars 2024) et pr茅cise que chaque action privil茅gi茅e se convertit en utilisant un prix initial par action de 1鈥�000 $ divis茅 par 4,90 $, sous r茅serve de clauses de blocage. La personne d茅clarant d茅cline la qualit茅 de propri茅taire b茅n茅ficiaire, 脿 l'exception d'un int茅r锚t p茅cuniaire.
Gaurav Aggarwal, Direktor von Unicycive Therapeutics, meldete in einem Form 4 einen nicht-derivativen Kauf von 652.900 Stammaktien am 25.08.2025. Nach der Transaktion weist die Meldung einen wirtschaftlich berechtigten Anteil von 1.789.915 Aktien aus, der indirekt 眉ber Vivo Opportunity Fund Holdings L.P. zugerechnet wird, bei dem die meldende Person gesch盲ftsf眉hrendes Mitglied ist. Die Einreichung berichtet au脽erdem 眉ber die Ver盲u脽erung von 3.199,21 Aktien der Series A-2 Prime Preferred Stock (ausgegeben am 14. M盲rz 2024) und erkl盲rt, dass jede Vorzugsaktie unter Verwendung des urspr眉nglichen St眉ckpreises von $1.000 geteilt durch $4,90 umgewandelt wird, vorbehaltlich Sperrklauseln. Die meldende Person weist die wirtschaftliche Berechtigung mit Ausnahme eines pecuni盲ren Interesses zur眉ck.
